← Back to Screener
ProKidney Corp. Class A Ordinary Shares (PROK)
Price$2.10
Favorite Metrics
Price vs S&P 500 (26W)-36.56%
Price vs S&P 500 (4W)3.46%
Market Capitalization$658.18M
All Metrics
Book Value / Share (Quarterly)$0.11
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.45
Price vs S&P 500 (YTD)-6.82%
Net Profit Margin (TTM)-7725.20%
EPS (TTM)$-0.51
10-Day Avg Trading Volume1.41M
EPS Excl Extra (TTM)$-0.51
EPS (Annual)$-0.52
ROI (Annual)-204.26%
Cash / Share (Quarterly)$0.90
Revenue Growth QoQ (YoY)196.05%
ROA (Last FY)-20.56%
EBITD / Share (TTM)$-1.18
Operating Margin (TTM)-18477.83%
Cash Flow / Share (Annual)$-0.45
P/B Ratio99.72x
P/B Ratio (Quarterly)322.02x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)615.58x
ROA (TTM)-18.83%
EPS Incl Extra (Annual)$-0.52
Current Ratio (Annual)9.13x
Quick Ratio (Quarterly)8.91x
3-Month Avg Trading Volume1.00M
52-Week Price Return173.90%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.10
P/S Ratio (Annual)737.04x
Asset Turnover (Annual)0.00x
52-Week High$7.13
EPS Excl Extra (Annual)$-0.52
CapEx CAGR (5Y)22.72%
26-Week Price Return-27.81%
Quick Ratio (Annual)8.91x
13-Week Price Return-4.39%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)9.13x
Enterprise Value$549.717
Asset Turnover (TTM)0.00x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-16931.47%
Cash / Share (Annual)$0.90
3-Month Return Std Dev75.30%
Net Income / Employee (TTM)$-0
ROE (Last FY)-205.02%
EPS Basic Excl Extra (Annual)$-0.52
Total Debt / Equity (Quarterly)5.40x
EPS Incl Extra (TTM)$-0.51
P/S Ratio (TTM)737.04x
Revenue / Share (Annual)$0.01
Tangible BV / Share (Annual)$-17.82
Price vs S&P 500 (52W)138.81%
Year-to-Date Return-2.68%
5-Day Price Return11.79%
EPS Normalized (Annual)$-0.52
ROA (5Y Avg)-40.11%
Net Profit Margin (Annual)-7725.20%
Month-to-Date Return21.79%
Cash Flow / Share (TTM)$-2.16
EBITD / Share (Annual)$-1.18
Operating Margin (Annual)-18477.83%
EPS Basic Excl Extra (TTM)$-0.51
P/TBV (Quarterly)337.35x
Pretax Margin (TTM)-16931.47%
Book Value / Share (Annual)$-17.82
Price vs S&P 500 (13W)-7.25%
Beta1.98x
Revenue / Share (TTM)$0.01
ROE (TTM)-28.10%
52-Week Low$0.54
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.93
3.93
3.93
3.93
Industry Peers — Biological Products(89)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
PROKProKidney Corp. Class A Ordinary Shares | 737.04x | — | — | — | $2.10 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
ProKidney Corp is a clinical-stage biotechnology company developing REACT, a patient-derived cell therapy designed to slow and stabilize the progression of chronic kidney diseases. The proprietary platform uses autologous renal cells to create personalized, disease-modifying treatments addressing a significant unmet medical need. The company's development pipeline is currently focused on severe diabetic kidney disease.